1. CYP-associated drug-drug interactions: A mission accomplished?
- Author
-
Pelkonen O, Hakkola J, Hukkanen J, and Turpeinen M
- Subjects
- Animals, Anti-Retroviral Agents, Antineoplastic Agents, Drug Evaluation, Preclinical, Finland, Humans, Pharmaceutical Preparations, Cytochrome P-450 CYP3A, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Drug Interactions
- Abstract
On the basis of official Finnish Medicines Authority (Fimea)-approved drug monographs, less than half of the approved small-molecule drugs between 2007 and 2016 were substrates, inhibitors or inducers of CYP enzymes, predominantly of CYP3A4. No significant unexpected, life-threatening, CYP-associated drug-drug interactions (CYP-DDIs) of newly approved drug entities have been observed in the last 10-15 years. The present analysis seems to suggest that tools to study and predict potentially significant CYP-DDIs are working and efficient.
- Published
- 2020
- Full Text
- View/download PDF